CD28 expression is required after T cell priming for helper T cell responses and protective immunity to infection

  1. Michelle A Linterman  Is a corresponding author
  2. Alice E Denton
  3. Devina P Divekar
  4. Ilona Zvetkova
  5. Leanne Kane
  6. Cristina Ferreira
  7. Marc Veldhoen
  8. Simon Clare
  9. Gordon Dougan
  10. Marion Espéli
  11. Kenneth G C Smith
  1. Babraham Institute, United Kingdom
  2. University of Cambridge, United Kingdom
  3. University of East Anglia, United Kingdom
  4. University of Cambridge Metabolic Research Laboratories, United Kingdom
  5. Wellcome Trust Sanger Institute, United Kingdom
  6. UMR-S996, LabEx LERMIT, France
  7. University of Cambridge School of Clinical Medicine, United Kingdom

Abstract

The costimulatory molecule CD28 is essential for activation of helper T cells. Despite this critical role, it is not known whether CD28 has functions in maintaining T cell responses following activation. To determine the role for CD28 after T cell priming we generated a strain of mice where CD28 is removed from CD4+ T cells after priming. We show that continued CD28 expression is important for effector CD4+ T cells following infection; maintained CD28 is required for the expansion of T helper type 1 cells, and for the differentiation and maintenance of T follicular helper cells during viral infection. Persistent CD28 is also required for clearance of the bacterium Citrobacter rodentium from the gastrointestinal tract. Together, this study demonstrates that CD28 persistence is required for helper T cell polarization in response to infection, describing a novel function for CD28 that is distinct from its role in T cell priming.

Article and author information

Author details

  1. Michelle A Linterman

    Babraham Institute, Cambridge, United Kingdom
    For correspondence
    Michelle.Linterman@babraham.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
  2. Alice E Denton

    University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Devina P Divekar

    University of East Anglia, Norwich, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Ilona Zvetkova

    University of Cambridge Metabolic Research Laboratories, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Leanne Kane

    Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Cristina Ferreira

    Babraham Institute, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Marc Veldhoen

    Babraham Institute, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Simon Clare

    Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Gordon Dougan

    Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Marion Espéli

    UMR-S996, LabEx LERMIT, Clamart, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Kenneth G C Smith

    University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: All experiments were performed according to the regulations of the UK Home Office Scientific Procedures Act (1986) under the UK Home Office license PPL 80/2438, or PPL 80/2596.

Copyright

© 2014, Linterman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,606
    views
  • 538
    downloads
  • 85
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Michelle A Linterman
  2. Alice E Denton
  3. Devina P Divekar
  4. Ilona Zvetkova
  5. Leanne Kane
  6. Cristina Ferreira
  7. Marc Veldhoen
  8. Simon Clare
  9. Gordon Dougan
  10. Marion Espéli
  11. Kenneth G C Smith
(2014)
CD28 expression is required after T cell priming for helper T cell responses and protective immunity to infection
eLife 3:e03180.
https://doi.org/10.7554/eLife.03180

Share this article

https://doi.org/10.7554/eLife.03180

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Mykhailo Vladymyrov, Luca Marchetti ... Britta Engelhardt
    Tools and Resources

    The endothelial blood-brain barrier (BBB) strictly controls immune cell trafficking into the central nervous system (CNS). In neuroinflammatory diseases such as multiple sclerosis, this tight control is, however, disturbed, leading to immune cell infiltration into the CNS. The development of in vitro models of the BBB combined with microfluidic devices has advanced our understanding of the cellular and molecular mechanisms mediating the multistep T-cell extravasation across the BBB. A major bottleneck of these in vitro studies is the absence of a robust and automated pipeline suitable for analyzing and quantifying the sequential interaction steps of different immune cell subsets with the BBB under physiological flow in vitro. Here, we present the under-flow migration tracker (UFMTrack) framework for studying immune cell interactions with endothelial monolayers under physiological flow. We then showcase a pipeline built based on it to study the entire multistep extravasation cascade of immune cells across brain microvascular endothelial cells under physiological flow in vitro. UFMTrack achieves 90% track reconstruction efficiency and allows for scaling due to the reduction of the analysis cost and by eliminating experimenter bias. This allowed for an in-depth analysis of all behavioral regimes involved in the multistep immune cell extravasation cascade. The study summarizes how UFMTrack can be employed to delineate the interactions of CD4+ and CD8+ T cells with the BBB under physiological flow. We also demonstrate its applicability to the other BBB models, showcasing broader applicability of the developed framework to a range of immune cell-endothelial monolayer interaction studies. The UFMTrack framework along with the generated datasets is publicly available in the corresponding repositories.

    1. Immunology and Inflammation
    Eugenio Antonio Carrera Silva, Juliana Puyssegur, Andrea Emilse Errasti
    Review Article

    The gut biome, a complex ecosystem of micro- and macro-organisms, plays a crucial role in human health. A disruption in this evolutive balance, particularly during early life, can lead to immune dysregulation and inflammatory disorders. ‘Biome repletion’ has emerged as a potential therapeutic approach, introducing live microbes or helminth-derived products to restore immune balance. While helminth therapy has shown some promise, significant challenges remain in optimizing clinical trials. Factors such as patient genetics, disease status, helminth species, and the optimal timing and dosage of their products or metabolites must be carefully considered to train the immune system effectively. We aim to discuss how helminths and their products induce trained immunity as prospective to treat inflammatory and autoimmune diseases. The molecular repertoire of helminth excretory/secretory products (ESPs), which includes proteins, peptides, lipids, and RNA-carrying extracellular vesicles (EVs), underscores their potential to modulate innate immune cells and hematopoietic stem cell precursors. Mimicking natural delivery mechanisms like synthetic exosomes could revolutionize EV-based therapies and optimizing production and delivery of ESP will be crucial for their translation into clinical applications. By deciphering and harnessing helminth-derived products’ diverse modes of action, we can unleash their full therapeutic potential and pave the way for innovative treatments.